Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients (Q35009131)

5 August 2017

title

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients (English)

1 reference

5 August 2017

0 references

16

Enrico Millefiorini

1 reference

5 August 2017

Orietta Picconi

7

0 references

Alessandra Lugaresi

object named as

Alessandra Lugaresi

2

0 references

Placido Bramanti

3

object named as

Placido Bramanti

1 reference

5 August 2017

13

Silvia Marino

1 reference

5 August 2017

14

Valentina Zipoli

1 reference

5 August 2017

Valentina Durastanti

1

1 reference

5 August 2017

Mariapia Amato

4

1 reference

5 August 2017

Paolo Bellantonio

5

1 reference

5 August 2017

Giovanna De Luca

6

1 reference

5 August 2017

Roberta Fantozzi

8

1 reference

5 August 2017

Laura Locatelli

9

1 reference

5 August 2017

Annalisa Solda'

10

1 reference

5 August 2017

Edoardo Sessa

11

1 reference

5 August 2017

Rocco Totaro

12

1 reference

5 August 2017

Marino Zorzon

15

1 reference

5 August 2017

publication date

18 April 2011

1 reference

Journal of Translational Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

page(s)

42

1 reference

Creative Commons Attribution 2.0 Generic

5 August 2017

copyright license

start time

18 April 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Neopterin, a prognostic marker in human malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Interferon-beta responders and non-responders. A biological approach

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Tryptophan degradation in autoimmune diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Therapeutic role of beta-interferons in multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Monitoring tryptophan metabolism in chronic immune activation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Neopterin as a marker for immune system activation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Biological markers in body fluids for activity and progression in multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-42

Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-42

Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-42

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-42

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-42

A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102623

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

26 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-9-42

CSF neopterin as marker of disease activity in multiple sclerosis

21 January 2018

1 reference

12 December 2020

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

12 December 2020

Simultaneous measurement of serum tryptophan and kynurenine by HPLC

1 reference

12 December 2020

The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems

1 reference

12 December 2020

Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes

1 reference

12 December 2020

Bioavailability of interferon-beta in patients with multiple sclerosis - fishing for the surrogate

1 reference

12 December 2020

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

12 December 2020

Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis

1 reference

12 December 2020

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

12 December 2020

Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms

1 reference

12 December 2020

Interleukin-2, soluble interleukin-2-receptor, neopterin,l-tryptophan and ?2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Identifiers

DOI

10.1186/1479-5876-9-42

1 reference

Dimensions Publication ID

5 August 2017

0 references

0 references

1 reference

5 August 2017

1 reference